sirolimus

Type: Keyphrase
Name: sirolimus
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

Bioresorbable stent developer Amaranth Medical initiates new clinical trial

Stent developer Amaranth Medical is launching the MEND-II clinical trial to test its Fortitude Sirolimus-Eluting Bioresorbable Scaffold, a sign that companies large and small are keenly eyeing the new treatment paradigm for coronary artery disease involving ... [Published FierceMedicalDevices - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

"Three Year Clinical Outcomes of a Unique Sirolimus-Eluting Stent with Fully Absorbable Polymer Coating: Long-term Results from the DESSOLVE I and the DESSOLVE II Clinical Trials" was presented in poster and oral formats as part of the Didactic Symposia, ... [Published Industrial Info Financials - Sep 16 2014]
Entities: Polymer, Stent, sirolimus, Drugs
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

SAKURA 1 study meets primary endpoint for treatment of noninfectious uveitis

LONDON — A study of intravitreal sirolimus for the treatment of noninfectious uveitis has achieved its primary endpoint, a speaker said here, reporting the data for the first time worldwide.At the Euretina Congress, Quan Dong Nguyen, MD, MSc, said a proportion ... [Published Orthopedics Today - Sep 15 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Pfizer agrees $35m settlement over Rapamune promotion

Pfizer has agreed to pay $35m to 41 US states, as well as the District of Columbia, in a settlement reached over claims that it improperly marketed and promoted the immunosuppressive drug Rapamune (sirolimus).The claims centre around allegations that ... [Published Pharmaceutical Journal - Sep 08 2014]
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Guiding Treatment of Advanced Breast Cancer Using Subtypes

Information contained on this page is provided by NewsUSA, an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith.( NewsUSA ) - For patients with breast cancer, knowing whether ... [Published WBAY Green Bay - Sep 07 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Sirolimus: A Therapeutic Advance for Dermatologic Disease

Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3 Suppl):7S-14S.Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor ... [Published General Medicine eJournal - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

BIOSCIENCE: DES With Biodegradable Polymer Matches Comparator

BARCELONA, SPAIN — One year results from the BIOSCIENCE study showed that an innovative stent with thinner-than-usual struts and a biodegradable polymer coating that releases the antiproliferative drug sirolimus within two years and then disappears ... [Published Diabetes Care - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Retrospective Review Of Combined Sirolimus And Simvastatin Therapy In Lymphangioleiomyomatosis

Background.   Combined simvastatin and sirolimus therapy reduce TSC2-null lesions and alveolar destruction in a mouse model of lymphangioleiomyomatosis (LAM), suggesting that therapy with both drugs may benefit LAM patients.Methods.   To determine whether ... [Published CHEST - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Patent Issued for Reduction in False Results in Assay Measurements

By a News Reporter-Staff News Editor at Biotech Week -- From Alexandria, Virginia , NewsRx journalists report that a patent by the inventor Wei, Tie Q. ( Wilmington, DE ), filed on November 2, 2012 , was published online on August 19, 2014 (see also Siemens ... [Published 4 Traders - Aug 28 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Using subtypes to guide treatment of advanced breast cancer

For patients with breast cancer, knowing whether the diagnosis is early stage or advanced is needed to help treat the disease.Vice-President and Chief Medical Officer for Georgia Cancer Specialists, Cheryl Jones, MD, has experience in treating patients ... [Published New Sarawak Tribune - Aug 24 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model [Coronary Interventions]

Background— Preclinical evaluation of the vascular response of drug-eluting stents is limited especially in the setting of diabetes mellituspreventing the evaluation of changes in drug-eluting stent design and eluted drugs after clinical use.Methods and ... [Published Circulation: Cardiovascular Interventions - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Researchers from Nanjing Medical University Report Details of New Studies and Findings in the Area of Coronary Artery Disease (Nine-month...

Researchers from Nanjing Medical University Report Details of New Studies and Findings in the Area of Coronary Artery Disease (Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus ...)By a News Reporter-Staff ... [Published 4 Traders - Aug 13 2014]

Quotes

...Stephen W L Lee , M D , of the Queen Mary Hospital, Hong Kong . "The COMBO Stent's unique approach shows early healing benefits and stability over the long-term. The results demonstrate no neoatherosclerosis observed by OCT at 24 months, and no late restenosis or stent thrombosis beyond 36 months. The COMBO Stent is the only DES which exhibits neointima regression from 9 months to 24 months. This is an indication of true vessel healing."
...oresorbable scaffold, while also providing the controlled release of sirolimus to reduce the risk of restenosis," said Amaranth CEO Kamal Ramzipoor. "We look forward to advancing FORTITUDE through this clinical trial and initiating a study next year in Europe, both of which will support our planned application for CE Mark."
...and chief innovation officer of the CRF-Skirball Center for Innovation (SCI) and primary investigator of the Amaranth clinical program, added, "We are encouraged by the positive results from MEND-I, especially in terms of the biocompatibility profile of the polymer. It is notable that FORTITUDE appears equivalent in its biological response to metal stents, which represents a significant leap forward in the advancement of the science and processing technology of these polymers. Further, while the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold is still in early stages of enrollment, it appears to have similar mechanical behavior but enhanced deliverability compared to the first-generation bare scaffold."
Dr. Ormiston commented, "The MiStent SES is the sole product among the new generation of bioabsorbable polymer DES to sustain local drug delivery beyond the presence of the polymer, providing therapeutic sirolimus drug levels in the tissue surrounding the stent for up to nine months. Full elimination of the polymer by three months - without loss of anti-restenotic drug effects - is different from any other DES formulation." About the MiStent SES

More Content

All (54) | News (43) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Latest Data Shows OrbusNeich's COMBO™ Dual Ther... [Published Fat Pitch Financials - 14 hours ago]
Cassava leaves, roots show promise against colo... [Published The Guardian Nigeria - 16 hours ago]
Bioresorbable stent developer Amaranth Medical ... [Published FierceMedicalDevices - Sep 16 2014]
Amaranth Medical Initiates Clinical Trial of th... [Published Industrial Info Financials - Sep 16 2014]
Micell Technologies Highlights Positive Three-Y... [Published Industrial Info Financials - Sep 16 2014]
SAKURA 1 study meets primary endpoint for treat... [Published Orthopedics Today - Sep 15 2014]
Ongoing Clinical Trials Actively Recruiting Pat... [Published The ASCO Post - Sep 15 2014]
Etanercept Plus Methotrexate More Effective on ... [Published American Journal of Public Health - Sep 12 2014]
Patent Application Titled "Drug Eluting Scaffol... [Published HispanicBusiness.com - Sep 10 2014]
Treatment of Dry Age-Related Macular Degeneration [Published Sexual Development - Sep 10 2014]
Pfizer agrees $35m settlement over Rapamune pro... [Published Pharmaceutical Journal - Sep 08 2014]
Guiding Treatment of Advanced Breast Cancer Usi... [Published WBAY Green Bay - Sep 07 2014]
Effect of DAPT on Stent Thrombosis According to... [Published General Medicine eJournal - Sep 04 2014]
Sirolimus: A Therapeutic Advance for Dermatolog... [Published General Medicine eJournal - Sep 03 2014]
The Generic Drug Labeling Carve-Out Scorecard [Published FDA Law Blog - Sep 02 2014]
BIOSCIENCE: DES With Biodegradable Polymer Matc... [Published Diabetes Care - Sep 02 2014]
The Lancet: European Society of Cardiology Cong... [Published EurekAlert! - Sep 02 2014]
Noxafil Tablets [Published Irish Medical Times - Sep 01 2014]
New-Generation DES Match BMS Stent Safety Beyon... [Published American Journal of Public Health - Aug 30 2014]
Muscular dystrophy sufferer aims to help patients [Published Shanghai Daily - Aug 28 2014]
Retrospective Review Of Combined Sirolimus And ... [Published CHEST - Aug 28 2014]
Patent Issued for Reduction in False Results in... [Published 4 Traders - Aug 28 2014]
Findings from F. Yuan and Co-Researchers Provid... [Published HispanicBusiness.com - Aug 28 2014]
A New Look at Phenotypic Screening [Published In the Pipeline - Aug 26 2014]
Studies from Peking University in the Area of C... [Published Pharmacy Choice - Aug 24 2014]
Using subtypes to guide treatment of advanced b... [Published New Sarawak Tribune - Aug 24 2014]
No Tumor-Free Waiting Period after Treatment of... [Published Sexual Development - Aug 21 2014]
Everolimus-Eluting Stents Improve Vascular Resp... [Published Circulation: Cardiovascular Interventions - Aug 20 2014]
Ongoing Clinical Trials Actively Recruiting Pat... [Published The ASCO Post - Aug 15 2014]
Effect of Solvent on Drug Release and a Spray-C... [Published Langmuir - Aug 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Generic Drug Labeling Carve-Out Scorecard [Published FDA Law Blog - Sep 02 2014]
By Kurt R. Karst –With the recent litigation surrounding FDA’s approval of ANDAs for generic versions of PRECEDEX (dexmedetomidine HCl) Injection – which litigation has now moved on to Motions for Summary Judgment (see our updates here for the latest ...
A New Look at Phenotypic Screening [Published In the Pipeline - Aug 26 2014]
There have been several analyses that have suggested that phenotypic drug discovery was unusually effective in delivering "first in class" drugs. Now comes a reworking of that question, and these authors (Jörg Eder, Richard Sedrani, and Christian ...
[Comment] Alemtuzumab induction therapy in kidn... [Published The Lancet online - Jul 28 2014]
In The Lancet, Peter Friend and the 3C Study Collaborative Group report the results of the first part of the 3C Study—an open-label, randomised, multicentre study of alemtuzumab compared with basiliximab induction treatment, followed by sirolimus versus ...
Svelte Medical Systems Announces Completion of ... [Published Venturebeat - May 29 2014]
SPONSORED POST Check out our  press release hub , powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop  here . NEW PROVIDENCE, N.J.–(BUSINESS ...
AADi, Celgene ink licensing deal for nanotechno... [Published PBR - News - May 21 2014]
US-based clinical stage biopharmaceutical firm AADi has entered into an inlicensing agreement with Celgene for ABI-009, a nanoparticle albumin-bound (nab) version of the mTOR inhibitor sirolimus or rapamycin. ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.